

Consolidated report of

MILESTONE MEDICAL INC. and its SUBSIDIARY

1st quarter (January 1, 2023 to March 31, 2023)

Report includes:

1. General information about Milestone Medical, Inc. (“Issuer”) and Milestone Medical Poland Sp. Z o.o. (the Subsidiary), collectively the Company or Milestone Medical.
2. Consolidated financial statements prepared according to the accounting rules applicable to the Issuer together with information on accounting rules (policy) applied to the preparation of report.
3. Information on the rules applied to the preparation of the report, including information on changes to the applied accounting rules (policies).
4. Brief description of the most important achievements or failures of the Issuer and its Subsidiary during the period of the report as well as a description of the most important factors and events, atypical ones, which affect the achieved results.
5. A description of the status of implementation of activities and investments of the Issuer and its Subsidiary and the timetable of their implementation.
6. If the Issuer and its Subsidiary took initiatives to develop, its activities aimed to implement innovative solutions at the enterprise during the period of the report – information on such activities.
7. Description of the organization of the group indicating consolidated entities.

New Jersey, May 15, 2023

1. General information

Table 1 General Information about the Issuer

THE ISSUER	MILESTONE MEDICAL INC.
	(Earlier: Milestone Scientific Research and Development, Inc.)
Registered office/Office:	425 Eagle Rock Avenue, Roseland, NJ 07068, USA
Telephone number:	011-973-535-2717
Facsimile number:	011-973-535-2829
E-mail:	kharcum@milestonescientific.com
Main website address:	www.medicalmilestone.com

Source: The Issuer

1.1 Shareholding structure

In the table below shares issued are outstanding for computing the ownership percentage of shareholders holding at least 5% of votes at the General Meeting of Shareholders, applicable percentages are based on 22,000,000 shares outstanding on the date of this annual report preparation. All percentages are rounded.

Table 2 Shareholder structure with specification of shareholders holding at least 5% of votes at the General Meeting of Shareholders at the date of the report.

Name of Shareholder	Number of owned shares/votes	Shareholding/votes at General Meeting of Shareholders [%]
MILESTONE SCIENTIFIC, INC.	21,633,084	98.33%
OTHERS (<5%)	366,916	1.67%
TOTAL	22,000,000	100.00%

Source: The Issuer

1.2. Board of Directors

Table 3 Board of Directors

NAME OF DIRECTOR	CURRENT AGE	DIRECTOR SINCE	END OF TERM
Zhu Yun	57	Sep -13	Next Annual Meeting of Shareholders
Martin S. Siegel	78	Sep -14	Next Annual Meeting of Shareholders

Source: The Issuer

On September 23, 2022 the Annual General Meeting of Shareholders adopted the resolution on the appointment of two directors: Zhu Yun and Martin S. Siegel, to the Board of Directors for new term of office. The resolution was entered into force on the date of adoption. The Directors to the Board have been elected to serve until the next Annual Meeting of Shareholders or until their respective successors have been elected and qualified.

1.3. Information on the number of persons employed by the Issuer converted into FTEs.

As of March 31, 2023, the Issuer employed three (3) full time employees and eleven (11) persons allocated from the parent company (Milestone Scientific Inc.) converted into full-time equivalents (“FTEs”). The Company is currently concentrating on certain territories in the USA and certain areas in the international market as well.

2. Condensed Consolidated quarterly financial statements

Condensed Consolidated quarterly financial statements prepared according to the accounting rules applicable to the Issuer and its Subsidiary together with information on accounting rules (policy) applied to the preparation of report.

Milestone Medical, Inc. and Subsidiary
Condensed Consolidated Financial Statements
As of March 31, 2023 and December 31, 2022, and
for the three months ended March 31, 2023 and 2022

<u>Table of Contents</u>	<u>Page</u>
Condensed Consolidated Financial Statements:	
Condensed Consolidated Balance Sheets	5
Condensed Consolidated Statements of Operations	6
Condensed Consolidated Statement of Changes in Stockholders' Deficit	7
Condensed Consolidated Statements of Cash Flows	8
Notes to Condensed Consolidated Financial Statements	9-16

Milestone Medical, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
(unaudited)

	March 31, 2023	December 31, 2022
<u>ASSETS</u>		
Cash	\$ 47,647	\$ 20,288
Accounts receivable	2,225	650
Inventories	429,379	404,461
Advances to contractors	75,686	75,686
Prepaid expenses and other current assets	134,368	115,904
Total current assets	689,305	616,989
Equipment, net	2,415	3,383
Total assets	\$ 691,720	\$ 620,372
<u>LIABILITIES AND STOCKHOLDERS' DEFICIT</u>		
Accounts payable	\$ 83,665	\$ 101,739
Accounts payable, related party	84	1,628
Accrued expenses and other payables	211,333	139,786
Accrued expenses and other payables, related party	33,333	-
Accrued interest payable- related party	698,572	676,134
Advances from related party	23,532,448	22,736,885
Due to related party	2,800,000	2,800,000
Total current liabilities	\$ 27,359,435	\$ 26,456,172
Commitments		
Stockholders' deficit		
Common stock, par value \$.0001; authorized 50,000,000 shares; 22,000,000 shares issued and outstanding at March 31, 2023, and December 31, 2022.	2,200	2,200
Additional paid-in capital	7,547,654	7,533,363
Accumulated deficit	(34,217,569)	(33,371,363)
Total stockholders' deficit	(26,667,715)	(25,835,800)
Total liabilities and stockholders' deficit	\$ 691,720	\$ 620,372

See Notes to Condensed Consolidated Financial Statements

Milestone Medical, Inc. and Subsidiary
Condensed Consolidated Statements of Operations
(Unaudited)

	Three months ended March 31, 2023	Three months ended March 31, 2022
Product sales, net	\$ 6,200	\$ 7,550
Cost of products sold	5,993	2,786
Gross profit	\$ 207	\$ 4,764
Selling, general and administrative expenses	809,568	1,231,885
Research and development expenses	11,604	7,950
Depreciation and amortization	968	1,019
Total operating expenses	\$ 822,140	\$ 1,240,854
Loss from operations	(821,933)	(1,236,090)
Interest expense	(24,273)	(23,887)
Loss before income tax	\$ (846,206)	\$ (1,259,977)
Provision for income taxes	-	-
Net loss	\$ (846,206)	\$ (1,259,977)
Net loss per share applicable to common stockholders		
Basic	(0.04)	(0.06)
Weighted average shares outstanding		
Basic	22,000,000	22,000,000

See Notes to Condensed Consolidated Financial Statements

Milestone Medical, Inc. and Subsidiary
Condensed Consolidated Statements of Changes in Stockholders' Deficit
(Unaudited)

	Common Stock Shares	Common Stock Amount	Additional Paid in Capital	Accumulated Deficit	Total
Balance, January 1, 2023	22,000,000	\$ 2,200	\$ 7,533,363	\$ (33,371,363)	\$ (25,835,800)
Stock Compensation from Parent	-	-	14,291		14,291
Net loss	-	-		(846,206)	(846,206)
Balance, March 31, 2023	<u>22,000,000</u>	<u>\$ 2,200</u>	<u>\$ 7,547,654</u>	<u>\$ (34,217,569)</u>	<u>\$ (26,667,715)</u>

	Common Stock Shares	Common Stock Amount	Additional Paid in Capital	Accumulated Deficit	Total
Balance, January 1, 2022	22,000,000	\$ 2,200	\$ 7,502,363	\$ (28,486,275)	\$ (20,981,712)
Stock Compensation from Parent	-	-	57,921	-	57,921
Net loss	-	-	-	(1,259,977)	(1,259,977)
Balance, March 31, 2022	<u>22,000,000</u>	<u>\$ 2,200</u>	<u>\$ 7,560,284</u>	<u>\$ (29,746,252)</u>	<u>\$ (22,183,768)</u>

See Notes to Condensed Consolidated Financial Statements

Milestone Medical, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows
(Unaudited)

	Three months ended March 31, 2023	Three months ended March 31, 2022
Cash flows from operating activities:		
Net loss	\$ (846,206)	\$ (1,259,977)
Adjustments to reconcile net cash operating activities:		
Depreciation and amortization expense	968	1,019
Stock Compensation from Parent	14,291	57,921
Changes in operating assets and liabilities:		
(Increase) decrease in accounts receivable	(1,575)	8,261
(Increase) decrease in inventories	(24,918)	27,980
(Increase) decrease to prepaid expenses and other current assets	(18,464)	19,161
Increase (decrease) in accounts payable and accrued expenses	53,473	(22,817)
Increase in accounts payable and accrued expenses, related party	31,789	52,309
Increase in accrued interest related party	22,438	22,438
Net cash used in operating activities	<u>\$ (768,204)</u>	<u>\$ (1,093,705)</u>
Cash flows from investing activities:		
Net cash used in investing activities	<u>\$ -</u>	<u>\$ -</u>
Cash flows from financing activities:		
Advances from parent	795,563	1,078,498
Net cash provided by financing activities	<u>\$ 795,563</u>	<u>\$ 1,078,498</u>
Net (decrease) increase in cash	27,359	(15,207)
Cash at beginning of period	20,288	35,448
Cash at end of period	<u>\$ 47,647</u>	<u>\$ 20,241</u>

See Notes to Condensed Consolidated Financial Statements

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For three months ended March 31, 2023 and 2022

NOTE 1 – ORGANIZATION AND BUSINESS:

In March 2011, Milestone Scientific Inc entered into an agreement with Beijing 3H Scientific Technology Co, Ltd (“ Beijing 3H”) a medical equipment distribution company organized in the People’s Republic of China (“PRC”), to establish a medical joint venture entity now named Milestone Medical Inc. (the “Company”) to develop intra-articular and epidural drug delivery instruments. The controlling shareholders of Beijing 3H and other shareholders contributed \$1.5 million in cash for a 50% ownership interest in this medical joint venture and Milestone Scientific Inc. contributed a royalty – free right to use its patented CompuFlo Technology, which was valued initially at \$1.5 million for the remaining 50% ownership interest

In June 2013, the Company changed its name to Milestone Medical Inc. The Company changed its Certificate of Incorporation to authorize 50,000,000 common shares, par value \$0.0001 per share and authorized 5,000,000 Preferred Shares, (preferred stock) at \$0.0001 per share in September 2013. Additionally, the common stock outstanding was split 10,000 to 1 into an aggregate of 20,000,000 shares. All periods presented have been recast to reflect these changes.

In October and November 2013, the Company raised \$2,363,206 in net proceeds (gross funding was \$3 million) through a Private Placement Offering. The offering resulted in the issuance of 2 million shares of common stock at \$1.50 (4.65 PLN) per share in a private placement in Poland.

On June 17, 2016, Milestone Scientific initiated a share exchange program pursuant to which would exchange one share of Milestone Scientific Inc. common stock for every two outstanding shares of Milestone Medical common stock. As of December 31, 2017, 5,319,042 shares of Milestone Scientific common stock have been issued in exchange for 10,638,084 shares of Milestone Medical common stock. Because of these exchanges, Milestone Scientific owns approximately 99% of Milestone Medical at December 31, 2017.

The Company received notification from the FDA in December 2016 that based upon the 510(k)-application submitted for the Company's Compu-Flo Intra Articular Computer Controlled Injection System, the Company did not adequately document that the device met the equivalency standard required for 510(k) clearances. The Company provided an additional data submission to the FDA in April 2017, in support of a resubmission 510(k) application for the device. The Company has decided not to proceed with securing the FDA approval for the intra-articular instrument at this time.

On June 12, 2017, the company announced that the CompuFlo® Epidural Computer Controlled Anesthesia System has received 510(k) clearances from the U.S. Food and Drug Administration (FDA). The CompuFlo® Epidural System provides anesthesiologists and other Health Care Providers for the first time, the ability to quantitatively determine and document the pressure at the needle tip in real-time. The CompuFlo® Epidural's proprietary DPS Dynamic Pressure Sensing Technology™ (DPS) allows the CompuFlo® Epidural to provide objective visual and audible in-tissue pressure feedback that allows anesthesiologists to identify the epidural space.

Milestone Medical’s immediate focus is on marketing its epidural device throughout the United States and Europe. The Company is in the process of attending medical device trade shows and attending introductory meetings with medical device distributors within the United States, Europe, and other international markets. The Company’s focus will be on marketing the Epidural medical and trainer instruments in the United States.

NOTE 2 - LIQUIDITY AND GOING CONCERN:

The Company has evaluated whether there are conditions or events, considered taken together, which raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. Milestone Medical has incurred significant operating losses since its inception. As of March 31, 2023, cash on hand was \$47,647 with negative working capital of approximately \$26.7 million.

As of March 31, 2023, the Company does not have sufficient cash to meet all its anticipated obligations for the next twelve months from the financial statement release date. These factors raise substantial doubt about the Company's ability to continue as a going concern. Milestone Medical will continue to manage its cash position while taking strategic steps to commercialize the Epidural instrument in the USA and throughout the world.

If Milestone Scientific, Inc. does not or is not able to lend appropriate amounts of funding and Milestone Medical is unable to obtain other sources of funding, there will be a material adverse effect on the Company. The financial statements do not include any adjustments relating to recoverability and classification of assets carrying amounts or the amounts and classification of liabilities that might result should the company be unable to continue as a going concern.

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present such interim results. Interim results are not necessarily indicative of the results of operations which may be expected for a full year or any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2022, included in Milestone Medical's Annual Report filed on March 21, 2023.

Basis of Consolidation

The Company owns seventy-five percent of a special purpose company organized in Poland, Milestone Medical Poland Sp. z.o.o., which is not active at this time.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to inventory realization and cash flow assumptions regarding going concern considerations. Actual results could differ from estimates.

Inventories

Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or net realizable value. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence, and product expiration requirements. The valuation allowance creates a new cost basis for the inventory, and it is not subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. The valuation allowance is only reduced if or when the underlying inventory is sold or destroyed.

Advances to Contractors

The advances to contractors represent funding to a subcontractor for parts required for epidural instrument manufacturing and repairs. On March 31, 2023, and December 31, 2022, advances to contractors was \$75,686.

Equipment, net

Equipment, net is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two to seven years. Depreciation expense was approximately \$1,000 for the three months ended March 31, 2023, and 2022, respectively. The costs of maintenance and repairs are charged to operations as incurred.

Revenue Recognition

The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To assess revenue recognition for its customer arrangements, the Company performs the following five steps:

- i. identification of the promised goods or services in the contract;
- ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; a performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account;
- iii. measurement of the transaction price, including the constraint on variable consideration;
- iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and
- v. recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company derives its revenues from the sale of its products, primarily medical instruments, handpieces/disposables, and other related products. The Company sells its products primarily through medical facilities and a global distribution network. Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are FOB destination, revenue is recognized upon delivery.

The Company has no obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. The Company's only obligation after sale, except for specific contracts and arrangements that provide for customer right to return provisions, is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period. We generally do not accept non-defective returns from our customers. Product returns under warranty are accepted, evaluated, and repaired or replaced in accordance with the Company's warranty policy. Returns not within the warranty policy are evaluated and the customer is charged for repair.

Sales Returns

The Company records allowances for product returns as a reduction of revenue at the time the product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers' return rights, the Company's historical experience with returns and the amount of product in the distribution channel not consumed by end users and subject to return.

The Company relies on historical return rates to estimate returns. In the future, if any of these factors and/or the history of product returns change, an adjustment to the allowance for product returns may be required.

Financing and Payment

Our payment terms differ by geography and customer, but payment is generally required within 90 days from the date of shipment or delivery.

Costs to Obtain or Fulfill a Customer Contract

Sales commissions are expensed when incurred because the amortization period would be one year or less. These costs are recorded in selling, general and administrative expense in the condensed consolidated statements of operations.

Shipping and handling costs, if any, are paid by or billed to customers at the time of shipment. Domestic and international shipments are FOB shipping point. The Company accounts for any shipping and handling activities related to contracts with customers as fulfillment costs which are included in cost of products sold in the condensed consolidated statements of operations.

Disaggregated Revenue Information

	Three months ended March 31, 2023	Three months ended March 31, 2022
Domestic: US		
Instruments	\$ 1,000	\$ -
Handpieces	1,200	7,550
Grand Total	<u>\$ 2,200</u>	<u>\$ 7,550</u>
International: Rest of World		
Instruments	\$ -	\$ -
Handpieces	4,000	-
Grand Total	<u>\$ 4,000</u>	<u>\$ -</u>
Total Product Sales	<u>\$ 6,200</u>	<u>\$ 7,550</u>

Research and Development

Research and development costs, which consist principally of new product development costs payable to third parties, are expensed as incurred. Advance payments for the research are amortized to expense either as services are performed or over the relevant service period using the straight-line method.

Income Taxes

Milestone Medical accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future

based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company and its Parent Company file a federal income tax return on a consolidated basis. State Income Taxes are filed on a separate company tax return. Income taxes are calculated on a separate return basis.

Deferred tax assets and liabilities are recognized as temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities. The Company currently does not recognize certain deferred tax assets because they file a consolidated tax return with Milestone Scientific, Inc., and does not have the legal ability to utilize the deferred tax assets.

On March 31, 2023 and 2022, we had no uncertain tax positions that required recognition in the condensed consolidated financial statements. The Company's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the statement of operations. Tax returns for 2019, 2020 and 2021 years are subject to audit by federal and state jurisdictions.

Stock-Based Compensation

Share-based payments to employees and third parties for services are recognized in the Statements of Operations over the service period, as an operating expense, based on the grant-date fair values. The Stock-based compensation has been allocated to Milestone Medical for employees and officers of Milestone Scientific, Inc. that have provided services to Milestone Medical and were issued stock options and restricted stock awards of Milestone Scientific, Inc.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"), which amends the guidance on measuring credit losses for certain financial assets measured at amortized cost, including trade receivables. The FASB has subsequently issued several updates to the standard, providing additional guidance on certain topics covered by the standard. This update requires entities to recognize an allowance for credit losses using a forward-looking expected loss impairment model, taking into consideration historical experience, current conditions, and supportable forecasts that impact collectability.

In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic, 326), Derivatives and hedging (Topic 815), and Leases (Topic 842): Effective dates, which deferred the effective date of ASU 2016-13 for the Company. As a result of ASU 2019-10, ASU 2016-13 is effective for all entities with fiscal years beginning after December 15, 2022, including interim periods. As January 1, 2023, the Company adopted ASU 2019-10, Financial Instruments - Credit Losses (Topic, 326), Derivatives and hedging (Topic 815), and Leases (Topic 842) the adoption of this ASU will not have a material impact on our financial statements.

NOTE 4 - INVENTORIES:

Inventories, net consist of the following:

Inventory	March 31, 2023	December 31, 2022
Inventories consists of the following:		
Epidural instruments	\$ 228,012	\$ 232,153
Epidural instruments - Trainer	1,626	1,626
Intra-articular instruments, net reserve	-	-
Epidural instruments Disposables	94,728	100,344
Component parts and other materials	103,799	69,124
Component parts and other materials - Trainer	1,214	1,214
Total	\$ 429,379	\$ 404,461

There is a full reserve for all intra-articular instrument which was approximately \$450,000 for the period ended March 31, 2023, and December 31, 2022. The Company has an inventory reserve for epidural instruments and handpieces as of March 31, 2023, and December 31, 2022 for approximately \$582,000.

NOTE 5 - RELATED PARTY TRANSACTIONS:

On December 31, 2014, Milestone Scientific, Inc. executed a \$2 million line of credit agreement to provide bridge financing to the Company through April 15, 2016. Borrowings under the line bear interest at a rate of 3.25%, the prime rate at the inception of the agreement. In September 2015, the company requested and received approval from the Board of Directors of Milestone Scientific, Inc. to increase the limit of the line of credit increased to \$2.5 million. In January 2016, the credit agreement was again increased to \$3 million hold.

As of March 31, 2023 and December 31, 2022, \$2.8 million is outstanding as due to - related party on the accompany condensed consolidated balance sheets. Additionally, as of March 31, 2023 and December 31, 2022, the Company owes accrued interest on the line of credit of approximately \$699,000 and \$676,000, which is reported as accrued interest payable- related party on the condensed consolidated balance sheets. Interest is payable based on availability of funds. No interest has been paid to the parent Company since the inception of the loan. As of the financial report issuance date, Milestone Scientific, Inc. has not demanded payment of the line of credit.

The technology underlying the CompuFlo®, and an improvement to the controls for CompuDent® were developed by the Director of Clinical Affairs and assigned to the Parent Company. Milestone Medical purchased a license to this technology pursuant to an agreement dated January 1, 2005. The Director of Clinical Affairs will receive payments of 5% of the total sales of the Company's products until the expiration of the last patent carried by Milestone Scientific, Inc. The Director of Clinical Affairs' royalty fee was approximately \$310 and \$380 for the three months ended March 31, 2023 and 2022 respectively.

Also, as of March 31, 2023 and December 31, 2022, the Company owes approximately \$23.5 million and \$22.7 million, respectively, to Milestone Scientific, Inc. for expenses and cash advances paid on the Company's behalf. As of the financial report issuance date, Milestone Scientific, Inc. has not demanded payment from the Company and these advances bear no interest.

NOTE 6 – CONCENTRATIONS AND SUPPLY UNCERTAINTIES:

Certain COVID-19 pandemic-related impacts were experienced by our businesses during 2023 and may continue to do so for an indeterminable period thereafter. These included supply chain delays for some of our products which are manufactured in China and supply shortages in key components in our medical products. Future resurgences in COVID-19 infections or other new viral outbreaks may affect the prioritization of non-acute versus acute healthcare utilization, which may temporarily weaken future demand for certain of our products and increase the demand for other of our products. Also, adverse macroeconomic conditions may worsen if governments impose future restrictions, such as lockdowns or quarantine requirements, in order to control infection rates associated with COVID-19 or other viruses.

Additionally, the pandemic escalated challenges that existed for global healthcare systems prior to the pandemic, including budget constraints and staffing shortages, particularly shortages of nursing staff. Changes in the ways healthcare services are delivered, including the transition of more care from acute to non-acute settings and increased focus on chronic disease management, may place additional financial pressure on hospitals and the broader healthcare system. Healthcare institutions may take actions to mitigate any persistent pressures on their budgets and such actions could impact the future demand for our products.

We are experiencing supply delays and shortages due to the disruptions the ongoing COVID-19 pandemic is having on the global supply chain, especially with respect to goods from China. The ongoing COVID-19 pandemic has resulted in significant disruption to the operations of certain suppliers in China and the related transportation of their goods to the United States that are parts of our global supply chain. We have been able to make alternative delivery arrangements for limited quantities of goods, at increased cost. While we have not yet experienced material shortages in supply as a result of these disruptions and our alternative delivery arrangements, if they were to be prolonged or expanded in scope, there could be resulting supply shortages which could impact our ability to have manufactured and delivered our products to the United States and, ultimately to our customers. Accordingly, such supply shortages and delivery limitations could have a material adverse effect on our business, financial condition, results of operations, and cash flows.

Milestone Medical has informal arrangements with third-party manufacturers of the epidural, and intra-articular devices, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. Consequently, advances on contracts have been classified as current March 31, 2023 and December 31, 2022.

The termination of the manufacturing relationship with any of these manufacturers could have a material adverse effect on Milestone Medical's ability to produce and sell its products. Although alternate sources of supply exist, and new manufacturing relationships could be established, Milestone Medical would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay.

Any curtailment or interruption of the supply, because of termination of such a relationship, would have a material adverse effect on Milestone Medical's financial condition, business, and results of operations.

For the three months ended March 31, 2023, 100% of net product sales were to two customers/distributors, 35%, and 65%, respectively. For the three months ended March 31, 2022, 100% of net product sales were to four customers/distributors, 43%, 23%, 17% and 17%, respectively.

At March 31, 2023, and December 31, 2022, we had one customer account for 100% of accounts receivable.

NOTE 7 – STOCK BASED COMPENSATION:

Stock-based compensation cost is measured at the grant date on the fair value of the award. Generally, compensation expense is recognized over the vesting period. The stock compensation has been allocated to Milestone Medical for officers and employees of Milestone Scientific, Inc. that have provided services to Milestone Medical and were issued stock options and restricted stock awards of Milestone Scientific, Inc.

Milestone Scientific recognizes compensation expense over the requisite service period. For three months ended March 31, 2023 and 2022, Milestone Scientific recognized \$4,900, and \$36,000 of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations.

As of March 31, 2023, there were 49,616 restricted shares granted and deferred under the terms of an employment agreement with the Territory Manager of Milestone Scientific. Such shares will be issued to each party upon completion of 2 years of employment. For the three months ended March 31, 2023, the Company recognized stock compensation expense of approximately \$9,400. As of March 31, 2023, the total unrecognized compensation expense was approximately \$28,100 related to unvested restricted stock awards, which the Company expects to recognize over an estimated weighted-average period of .78 years.

NOTE 8 - COMMITMENTS:

On April 6, 2021, Leonard Osser and Milestone Scientific, Inc. restructured the U.S. Asian Consulting Group, LLC, agreements originally signed July 10, 2017, with the Company. The Consulting Agreement dated as of July 10, 2017 (the “Consulting Agreement”) between the Company and U.S. Asian Consulting Group, LLC, a company of which Mr. Osser is a principal, the compensation increased by \$100,000 to \$200,000, equally split between a cash amount and an amount in shares of Milestone Scientific, Inc. common stock. Compensation under the Consulting Agreement are payable for 9.5 years from the date Mr. Osser steps down as Interim-CEO. Leonard Osser resigned as Interim Chief Executive Officer of the Company effective May 19, 2021. The Company recorded expense of \$50,000 related to the US Asian Consulting Group, LLC for the three months ended March 31, 2023, and 2022.

NOTE 9 – SUBSEQUENT EVENTS:

After March 31, 2023 Milestone Scientific, Inc. has advanced Milestone Medical approximately \$90,000 to support the commercialization process for the epidural instrument and other expenses necessary for the day-to-day operations of the Company.

3. Information on the rules applied to the preparation of the report, including information on the changes in applied account rules (policies)

Condensed Consolidated quarterly report for the first quarter of 2023 was prepared in accordance with the rules indicated in Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect market”. Information on applied accounting rules (policies) are presented in Note 3 to the Financial Statement.

4. Brief description of the most important achievements or failures of the Issuer and its Subsidiary during the period of the report as well as a description of the most important factors and events, atypical ones, which impact the achieved results.

On February 27, 2023 the Company announced on ESPI/1/2023 announced that its CompuFlo Epidural System has received 510(k)FDA clearance for use in the thoracic region of the spine, including the cervical thoracic junction. This approval expands upon the Company's prior approval of CompuFlo for use within the lumbar region of the spine, where the focus has been on labor and delivery.

On March 2, 2023 the Company announced on ESPI/2/2023 announced that its CompuFlo Epidural System has been granted registration with the U.S. Government's System for Award Management ("SAM") . A SAM registration is required for entities to bid on contracts and conduct business with federal government agencies, including the Department of Defense, Department of Veterans Affairs, Indian Health Service and other government agencies.

On March 10, 2023 the Company announced on ESPI/3/2023 announced that it has commenced sales of CompuFlo Epidural disposables across three pain management clinics in Colorado: Spine Correction Center of the Rockies; Colorado Clinic; and Colorado Accident and Injury. Adoption of the technology by these clinics follows a successful evaluation process by Dr. Brad Sisson, MD, a recognized pain management doctor. Dr. Sisson initially conducted five cases using the CompuFlo Epidural instrument, in which he reported 100% success. The evaluation included procedures within the challenging thoracic region of the spine, following the recent FDA approval of the CompuFlo Epidural System for use in this indication.

On March 14, 2023 the Company announced on ESPI/4/2023 announced the commencement of sales of CompuFlo Epidural disposables within the University Pain and Spine Center which operates 7 locations across New Jersey and New York. Adoption of the technology follows a successful evaluation by Dr. Didier Demesmin, MD, MBA. Dr. Demesmin is an interventional pain medicine physician who is board-certified in both anesthesiology and pain medicine. He is also the medical director and founder of the University Pain and Spine Center and is also affiliated with some of the most well-respected hospitals in Central New Jersey, such as Robert Wood Johnson University Hospital, JFK Medical Center, Somerset Medical Center, and Saint Peter's University Hospital, where he is the director of pain medicine.

5. A description of the status of implementation of activities and investments of the Issuer and its Subsidiary and the timetable of their implementation

The Company remains focused on advancing efforts establishing Milestone’s platform painless and precise drug delivery, providing for the first time objective visual and audible in-tissue pressure feedback, and continuing to expand platform applications. Commercializing our CompuFlo Epidural System, a transformative device for epidural anesthesia procedures expanding the global footprint of our CompuFlo Epidural System by partnering with distribution companies worldwide.

6. If the Issuer and its Subsidiary took initiatives to develop its activities aimed to implement innovative solutions at the enterprise during the period of the report – information on such activities.

The Issuer and its Subsidiary continues to consider and where appropriate include innovative initiatives for its medical instrument in the EU community. The Company continues to work and introduce the Epidural instrument in key medical institutions in the United States.

7. Description of the organization of the group indicating consolidated entities

Up to the date of this report completion, the Issuer does have a special purpose subsidiary Milestone Medical Poland Sp. z.o.o. The purpose of this company is the application and acceptance of Polish Government Grants for research and development of the current and future improvements to the medical instruments. Below the Issuer presents some basic information about its subsidiary:

Table 6 General information about Subsidiary of the Issuer

SUBSIDIARY	MILESTONE MEDICAL POLAND SP. Z.O.O.
Registered office/Office:	Place Powstancow Slaskich 1/201, 53-329 Wroclaw
Telephone number:	48 (71)79 11 555
Facsimile number:	48 (71) 79 11 556
Percentage share of the Issuer in share capital	75 percent
Percentage share of the Issuer in the total number of votes	75 percent

Source: The Issuer

Milestone Medical Poland Sp. z.o.o. was established in September 2014 and is not active at the time. The Issuer has prepared Condensed Consolidated Financial Statements with this subsidiary according to laws and regulations applicable to the Issuer.

Jan A. Haverhals
Chief Executive Officer